Budesonide and fluticasone propionate differentially affect the airway epithelial barrier

BACKGROUND: COPD patients have a higher risk of pneumonia when treated with fluticasone propionate (FP) than with placebo, and a lower risk with budesonide (BUD). We hypothesized that BUD and FP differentially affect the mucosal barrier in response to viral infection and/or cigarette smoke. METHODS:...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Respir Res
Glavni autori: Heijink, I. H., Jonker, M. R., de Vries, M., van Oosterhout, A. J. M., Telenga, E., ten Hacken, N. H. T., Postma, D. S., van den Berge, M.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704248/
https://ncbi.nlm.nih.gov/pubmed/26739349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-015-0318-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items